The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

Blood

Volumn 126, Issue 13, 2015, Pages 1551-1554

  Deininger, Michael ^a   Radich, Jerald ^b   Burn, Timothy C ^c   Huber, Reid ^c   Paranagama, Dilan ^c   Verstovsek, Srdan ^d  

^a UNIVERSITY OF UTAH   (United States)

^b USA   (United States)

^c Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PLACEBO; RUXOLITINIB; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ALLELISM; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MYELOFIBROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ALLELE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; POINT MUTATION; PRIMARY MYELOFIBROSIS; SPLEEN; SPLENOMEGALY;

ALLELES; FEMALE; HUMANS; JANUS KINASE 2; MALE; POINT MUTATION; PRIMARY MYELOFIBROSIS; PYRAZOLES; SPLEEN; SPLENOMEGALY;

EID: 84942253314     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-635235     Document Type: Article

References (18)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673-683.
3. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
7. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
8. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
9. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871.
10. Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
11. V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res. 2011;35(2):177-182.
12. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
13. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477-1483.
14. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol. 2007;79(6):508-515.
15. Collier P, Patel K, Waeltz P, et al. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers. 2013;17(5):429-437.
16. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-1398.
17. Vannucchi AM, Passamonti F, Al-Ali HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in Comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT) [abstract]. Blood. 2012;120(21): Abstract 708.
18. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.